Annual General Meeting 2026

The Annual General Meeting in Oncopeptides AB (publ) will be held at Tändstickspalatset, Västra Trädgårdsgatan 15, Stockholm, Sweden on Thursday 21 May 2026 at 14:00 CET. Registration starts at 13:30 CET.

The shareholders in Oncopeptides AB (publ)(“Oncopeptides” or the “Company”) are hereby given notice to attend the Annual General Meeting. A shareholder may participate in the Annual General Meeting at the venue (in person or represented by a proxy) or through advance voting (postal voting).

Right to participate in the Annual General Meeting and notice of participation

Participation in the Annual General Meeting at the venue

A shareholder who wishes to participate in the Annual General Meeting at the venue (in person or represented by a proxy) must (i) be recorded as a shareholder in the share register prepared by Euroclear Sweden AB relating to the circumstances on 12 May 2026, and (ii) no later than 15 May 2026 give notice of its intention to participate through mail or e-mail.

Notice of intention to participate in the Annual General Meeting can be given:
– by mail addressed to Oncopeptides AB (publ), “AGM”, Luntmakargatan 46, SE-111 37 Stockholm, Sweden, and
– by e-mail to lisa.swedel@oncopeptides.com.

When providing such notice, the shareholder should state name, personal or corporate registration number, address, telephone number and the number of any accompanying assistant(s) (maximum two assistants) as well as information about any proxy. Shareholders who are represented by proxy must issue a written, dated proxy for the representative. Proxy forms are available at www.oncopeptides.com. The proxy should be sent to the Company as set out above well in advance of the Annual General Meeting. If the proxy is issued by a legal entity, a certificate of registration or an equivalent certificate of authority should be enclosed.

Participation by voting in advance

A shareholder who wishes to participate in the Annual General Meeting by voting in advance (postal voting) must (i) be recorded as a shareholder in the share register prepared by Euroclear Sweden AB relating to the circumstances on 12 May 2026, and (ii) notify its intention to participate in the Meeting no later than 15 May 2026, by casting its advance vote in accordance with the instructions below so that the advance voting form is received by the Company no later than on that day.

A shareholder who wishes to participate in the Annual General Meeting at the venue in person or represented by a proxy must give notice thereof in accordance with what is set out under Participation in the Annual General Meeting at the venue above. This means that a notification by advance vote is not sufficient for a person who wishes to participate at the venue.

A special form shall be used when voting in advance. The form is available on www.oncopeptides.com. A completed and signed form may be submitted via mail addressed to Oncopeptides AB (publ), “AGM”, Luntmakargatan 46, SE-111 37 Stockholm, Sweden, and by e-mail to lisa.swedel@oncopeptides.com. The completed form shall be received by Oncopeptides AB (publ) not later than 15 May 2026. The shareholder may not provide special instructions or conditions in the voting form. If so, the vote (i.e. the advance vote in its entirety) is invalid. Further instructions and conditions are included in the form for advance voting.

If a shareholder votes in advance by proxy, a written and dated proxy shall be enclosed to the advance voting form. Proxy forms are available at www.oncopeptides.com. If the shareholder is a legal entity, a certificate of incorporation or an equivalent certificate of authority should be enclosed.

If a shareholder has voted in advance and attends the Annual General Meeting in person or through a proxy, the advance vote is still valid except to the extent the shareholder participates in a voting procedure at the Meeting or otherwise withdraws its advance vote. If the shareholder chooses to participate in a voting at the Meeting, the vote cast will replace the advance vote with regard to the relevant item on the agenda.

Nominee registered shares

To be entitled to participate in the Meeting, in addition to providing notification of participation, a shareholder whose shares are held in the name of a nominee must register its shares in its own name so that the shareholder is recorded in the share register relating to the circumstances on 12 May 2026. Such registration may be temporary (so-called voting right registration) and is requested from the nominee in accordance with the nominee’s procedures and in such time in advance as the nominee determines. Voting right registrations completed by the nominee not later than 15 May 2026 are taken into account when preparing the register of shareholders.

Proposed agenda

1. Opening of the Annual General Meeting;
2. election of chairman of the Annual General Meeting;
3. preparation and approval of voting list;
4. approval of the agenda;
5. election of one or two persons to approve the minutes;
6. determination as to whether the Annual General Meeting has been duly convened;
7. presentation by the CEO;
8. presentation of the annual report and auditor’s report and of the group annual report and the group auditor’s report;
9. resolutions in respect of
   a. adoption of the profit and loss statement and balance sheet and the group profit and loss statement and group balance sheet;
   b. allocation of the Company’s profit or loss in accordance with the adopted balance sheet;
   c. the discharge from liability for the members of the Board of Directors and the CEO;
10. determination of the number of members of the Board of Directors and the number of auditors to be elected at the Annual General Meeting;
11. determination of directors’ and auditors’ fees;
12. election of members of the Board of Directors and Chairman of the Board of Directors;
    a. Per Wold-Olsen, re-election
    b. Brian Stuglik, re-election
    c. Per Samuelsson, re-election
    d. Christine Rankin, re-election
    e. Chairman of the Board of Directors: Per Wold-Olsen, re-election
13. election of auditor;
14. presentation of the Board of Directors’ remuneration report for approval;
15. resolution on principles for guidelines for remuneration to senior management;
16. resolution on the introduction of a long-term shareholder program Board RSU 2026 for members of the Board of Directors;
    a. proposal for resolution on adoption of a long-term shareholder program Board RSU 2026 for members of the Board of Directors
    b. proposal for resolution on transfer of own ordinary shares to participants in Board RSU 2026
    c. proposal regarding equity swap agreement with a third party
17. resolution on the introduction of a performance based long-term incentive program for the Company’s employees and consultants;
    a. proposal for resolution on adoption of a performance based long-term incentive program for the Company’s employees and consultants
    b. proposal for resolution on transfer of own ordinary shares to participants in Co-worker LTIP 2026
    c. proposal regarding equity swap agreement with a third party
18. resolution regarding authorisation for the Board of Directors to resolve upon issues of shares, warrants and/or convertibles;
    a. main proposal
    b. alternative proposal
19. closing of the Annual General Meeting.